CL2015000762A1 - Combinaciones farmacéuticas que comprenden aglutinantes duales de angiopoyetina-2/dll4 y agentes anti-vegf - Google Patents
Combinaciones farmacéuticas que comprenden aglutinantes duales de angiopoyetina-2/dll4 y agentes anti-vegfInfo
- Publication number
- CL2015000762A1 CL2015000762A1 CL2015000762A CL2015000762A CL2015000762A1 CL 2015000762 A1 CL2015000762 A1 CL 2015000762A1 CL 2015000762 A CL2015000762 A CL 2015000762A CL 2015000762 A CL2015000762 A CL 2015000762A CL 2015000762 A1 CL2015000762 A1 CL 2015000762A1
- Authority
- CL
- Chile
- Prior art keywords
- pharmaceutical combinations
- vegf agents
- dll4
- angiopoietin
- binders
- Prior art date
Links
- 102000009075 Angiopoietin-2 Human genes 0.000 title 1
- 108010048036 Angiopoietin-2 Proteins 0.000 title 1
- 239000011230 binding agent Substances 0.000 title 1
- 239000003795 chemical substances by application Substances 0.000 title 1
- 230000009977 dual effect Effects 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- A61K38/1761—Apoptosis related proteins, e.g. Apoptotic protease-activating factor-1 (APAF-1), Bax, Bax-inhibitory protein(s)(BI; bax-I), Myeloid cell leukemia associated protein (MCL-1), Inhibitor of apoptosis [IAP] or Bcl-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Endocrinology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Marine Sciences & Fisheries (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12186696 | 2012-09-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2015000762A1 true CL2015000762A1 (es) | 2015-08-07 |
Family
ID=46963603
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2015000762A CL2015000762A1 (es) | 2012-09-28 | 2015-03-25 | Combinaciones farmacéuticas que comprenden aglutinantes duales de angiopoyetina-2/dll4 y agentes anti-vegf |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20140093499A1 (es) |
| EP (1) | EP2900260A1 (es) |
| JP (1) | JP2015532273A (es) |
| KR (1) | KR20150060686A (es) |
| CN (1) | CN104661679A (es) |
| AR (1) | AR092737A1 (es) |
| AU (1) | AU2013322564A1 (es) |
| CA (1) | CA2883880A1 (es) |
| CL (1) | CL2015000762A1 (es) |
| EA (1) | EA201500371A1 (es) |
| IL (1) | IL237646A0 (es) |
| MX (1) | MX2015003894A (es) |
| PH (1) | PH12015500664A1 (es) |
| TW (1) | TW201427680A (es) |
| UY (1) | UY35055A (es) |
| WO (1) | WO2014049100A1 (es) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2700450T3 (es) | 2009-10-16 | 2019-02-15 | Oncomed Pharm Inc | Combinación terapéutica y uso de anticuerpos antagonistas de DLL4 y agentes antihipertensores |
| SI3485903T1 (sl) | 2011-09-23 | 2023-02-28 | Mereo Biopharma 5, Inc. | Sredstva, ki vežejo VEGF/DLL4, in njihove uporabe |
| EP3125937A4 (en) * | 2014-04-04 | 2017-11-01 | Oncomed Pharmaceuticals, Inc. | Treatment of gastric cancer |
| US9840553B2 (en) | 2014-06-28 | 2017-12-12 | Kodiak Sciences Inc. | Dual PDGF/VEGF antagonists |
| DK3212233T3 (da) | 2014-10-31 | 2020-07-27 | Oncomed Pharm Inc | Kombinationsterapi til behandling af sygdom |
| KR20170081253A (ko) | 2014-11-10 | 2017-07-11 | 에프. 호프만-라 로슈 아게 | 항-il-1베타 항체 및 이의 사용 방법 |
| CN107074941A (zh) | 2014-11-10 | 2017-08-18 | 豪夫迈·罗氏有限公司 | 双特异性抗体和用于眼科学的方法 |
| KR20170082594A (ko) * | 2014-11-10 | 2017-07-14 | 에프. 호프만-라 로슈 아게 | 항-ang2 항체 및 사용 방법 |
| WO2017053705A1 (en) | 2015-09-23 | 2017-03-30 | Oncomed Pharmaceuticals, Inc. | Methods and compositions for treatment of cancer |
| JP7088454B2 (ja) | 2015-12-30 | 2022-06-21 | コディアック サイエンシーズ インコーポレイテッド | 抗体および抗体複合体 |
| CN110691790A (zh) * | 2017-06-02 | 2020-01-14 | 勃林格殷格翰国际有限公司 | 抗癌联合治疗 |
| JP2021514656A (ja) | 2018-03-02 | 2021-06-17 | コディアック サイエンシーズ インコーポレイテッドKodiak Sciences Inc. | Il−6抗体ならびにその融合構築物およびコンジュゲート |
| EP4041312A4 (en) | 2019-10-10 | 2023-12-20 | Kodiak Sciences Inc. | METHOD FOR TREATING AN EYE DISORDER |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7803377B2 (en) * | 2006-06-06 | 2010-09-28 | Genentech, Inc. | Anti-DLL4 antibodies and methods using same |
| JP2009539870A (ja) * | 2006-06-06 | 2009-11-19 | ジェネンテック・インコーポレーテッド | 血管発生の調節ための組成物および方法 |
| CN102264763B (zh) * | 2008-09-19 | 2016-04-27 | 米迪缪尼有限公司 | 定向于dll4的抗体及其用途 |
| US8268314B2 (en) * | 2008-10-08 | 2012-09-18 | Hoffmann-La Roche Inc. | Bispecific anti-VEGF/anti-ANG-2 antibodies |
| JO3182B1 (ar) * | 2009-07-29 | 2018-03-08 | Regeneron Pharma | مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2 |
| EP2459191A1 (en) * | 2009-07-31 | 2012-06-06 | OSI Pharmaceuticals, LLC | Mtor inhibitor and angiogenesis inhibitor combination therapy |
| US20110172398A1 (en) * | 2009-10-02 | 2011-07-14 | Boehringer Ingelheim International Gmbh | Bispecific binding molecules for anti-angiogenesis therapy |
| AR080794A1 (es) * | 2010-03-26 | 2012-05-09 | Hoffmann La Roche | Anticuerpos bivalentes biespecificos anti- vegf/ anti-ang-2 |
| US20130078247A1 (en) * | 2011-04-01 | 2013-03-28 | Boehringer Ingelheim International Gmbh | Bispecific binding molecules binding to dii4 and ang2 |
| US9527925B2 (en) * | 2011-04-01 | 2016-12-27 | Boehringer Ingelheim International Gmbh | Bispecific binding molecules binding to VEGF and ANG2 |
-
2013
- 2013-09-26 KR KR1020157005607A patent/KR20150060686A/ko not_active Withdrawn
- 2013-09-26 WO PCT/EP2013/070144 patent/WO2014049100A1/en not_active Ceased
- 2013-09-26 EA EA201500371A patent/EA201500371A1/ru unknown
- 2013-09-26 MX MX2015003894A patent/MX2015003894A/es unknown
- 2013-09-26 AU AU2013322564A patent/AU2013322564A1/en not_active Abandoned
- 2013-09-26 EP EP13766386.0A patent/EP2900260A1/en not_active Withdrawn
- 2013-09-26 JP JP2015533597A patent/JP2015532273A/ja active Pending
- 2013-09-26 CA CA2883880A patent/CA2883880A1/en not_active Abandoned
- 2013-09-26 US US14/037,463 patent/US20140093499A1/en not_active Abandoned
- 2013-09-26 CN CN201380049946.0A patent/CN104661679A/zh active Pending
- 2013-09-27 TW TW102135176A patent/TW201427680A/zh unknown
- 2013-09-27 AR ARP130103516A patent/AR092737A1/es unknown
- 2013-09-27 UY UY0001035055A patent/UY35055A/es unknown
-
2015
- 2015-03-10 IL IL237646A patent/IL237646A0/en unknown
- 2015-03-25 PH PH12015500664A patent/PH12015500664A1/en unknown
- 2015-03-25 CL CL2015000762A patent/CL2015000762A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2013322564A1 (en) | 2015-03-12 |
| KR20150060686A (ko) | 2015-06-03 |
| CA2883880A1 (en) | 2014-04-03 |
| IL237646A0 (en) | 2015-04-30 |
| TW201427680A (zh) | 2014-07-16 |
| EA201500371A1 (ru) | 2015-08-31 |
| US20140093499A1 (en) | 2014-04-03 |
| AR092737A1 (es) | 2015-04-29 |
| JP2015532273A (ja) | 2015-11-09 |
| EP2900260A1 (en) | 2015-08-05 |
| WO2014049100A1 (en) | 2014-04-03 |
| CN104661679A (zh) | 2015-05-27 |
| UY35055A (es) | 2014-03-31 |
| MX2015003894A (es) | 2015-07-17 |
| PH12015500664A1 (en) | 2015-05-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2015000762A1 (es) | Combinaciones farmacéuticas que comprenden aglutinantes duales de angiopoyetina-2/dll4 y agentes anti-vegf | |
| LT2892923T (lt) | Il-18 surišančios molekulės | |
| BR112014026532A2 (pt) | artigo para fumar | |
| SMT202000512T1 (it) | Anticorpi anti-tau umani | |
| FI3485903T3 (fi) | Vegf/dll4 -sitovat aineet ja niiden käyttö | |
| EP3275481C0 (en) | AUTO-INJECTOR | |
| BR112014030917A2 (pt) | artigo absorvente | |
| EP2884175A4 (en) | BURNER | |
| HUE037304T2 (hu) | Új keményforrasztási koncepció | |
| EP2805700A4 (en) | DISPOSABLE USE ITEMS | |
| BR112014026835A2 (pt) | artigo absorvente | |
| PT2831113T (pt) | Anticorpos para ligandos do recetor b1 da bradicinina | |
| PT2931313T (pt) | Formulações de solução de anticorpos anti-il-23p19 modificados | |
| CL2015000761A1 (es) | Combinaciones farmacéuticas que comprenden aglutinantes duales de angiopoyetina-2/dll4 y agentes anti-vegf-r | |
| DK2897594T3 (da) | Farmaceutisk sammensætning | |
| DK3431504T3 (da) | Antiphospholipase d4-antistof | |
| DK2717245T3 (da) | Farveefterglødende genstand | |
| HRP20190050T1 (hr) | Farmaceutski pripravci za kombinacijsku terapiju | |
| EP2883547A4 (en) | MEDICINE | |
| BR112014028441A2 (pt) | composição de proteína | |
| FR2990865B1 (fr) | Autoinjecteur | |
| FR2990868B1 (fr) | Autoinjecteur | |
| FR2990869B1 (fr) | Autoinjecteur | |
| FR2990866B1 (fr) | Autoinjecteur | |
| FR2990863B1 (fr) | Autoinjecteur |